Literature DB >> 16602931

Glucagon-like Peptide-2.

Jennifer L Estall1, Daniel J Drucker.   

Abstract

Multiple peptide hormones produced within the gastrointestinal system aid in the regulation of energy homeostasis and metabolism. Among these is the intestinotrophic peptide glucagon-like peptide-2 (GLP-2), which is released following food intake and plays a significant role in the adaptive regulation of bowel mass and mucosal integrity. The discovery of GLP-2's potent growth-promoting and cytoprotective effects in the gastrointestinal (GI) tract stimulated interest in its use as a therapeutic agent for the treatment of GI diseases involving malabsorption, inflammation, and/or mucosal damage. Current research has focused on determining the physiological mechanisms contributing to the effects of GLP-2 and factors regulating its biological mechanisms of action. This chapter provides an overview of the biology of GLP-2 with a focus on the most recent findings on the role of this peptide hormone in the normal and diseased GI tract.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16602931     DOI: 10.1146/annurev.nutr.26.061505.111223

Source DB:  PubMed          Journal:  Annu Rev Nutr        ISSN: 0199-9885            Impact factor:   11.848


  28 in total

Review 1.  Recent advances in gut nutrient chemosensing.

Authors:  C A Nguyen; Y Akiba; J D Kaunitz
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas.

Authors:  J de Heer; J Pedersen; C Orskov; J J Holst
Journal:  Diabetologia       Date:  2007-08-04       Impact factor: 10.122

3.  Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates.

Authors:  Andreas Vegge; Thomas Thymann; Pernille Lund; Barbara Stoll; Stine B Bering; Bolette Hartmann; Jacob Jelsing; Niels Qvist; Douglas G Burrin; Palle B Jeppesen; Jens J Holst; Per T Sangild
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-06-13       Impact factor: 4.052

4.  Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure.

Authors:  Adam S Brinkman; Sangita G Murali; Stacy Hitt; Patrick M Solverson; Jens J Holst; Denise M Ney
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-28       Impact factor: 4.052

Review 5.  Animal models of gastrointestinal and liver diseases. Animal models of infant short bowel syndrome: translational relevance and challenges.

Authors:  Per T Sangild; Denise M Ney; David L Sigalet; Andreas Vegge; Douglas Burrin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-10-23       Impact factor: 4.052

6.  Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1-, 5-HT-, and neurotensin-expressing enteroendocrine cells in rats.

Authors:  M B Mumphrey; L M Patterson; H Zheng; H-R Berthoud
Journal:  Neurogastroenterol Motil       Date:  2012-10-24       Impact factor: 3.598

7.  Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis.

Authors:  Eva Tomas; Joel F Habener
Journal:  Trends Endocrinol Metab       Date:  2009-12-16       Impact factor: 12.015

8.  Whey protein potentiates the intestinotrophic action of glucagon-like peptide-2 in parenterally fed rats.

Authors:  Xiaowen Liu; Sangita G Murali; Jens J Holst; Denise M Ney
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-09-23       Impact factor: 3.619

9.  Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells.

Authors:  Jacqueline A Koehler; Will Harper; Maja Barnard; Bernardo Yusta; Daniel J Drucker
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

10.  Glucose sensing in L cells: a primary cell study.

Authors:  Frank Reimann; Abdella M Habib; Gwen Tolhurst; Helen E Parker; Gareth J Rogers; Fiona M Gribble
Journal:  Cell Metab       Date:  2008-12       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.